Introduction - 15/08/11
Doi : 10.1016/j.amjcard.2007.03.001
Robert P. Byington, MPH, PhD a, ⁎ 
, Saul Genuth, MD b, William T. Friedewald, MD c, Denise G. Simons-Morton, MD, PhD d
, Saul Genuth, MD b, William T. Friedewald, MD c, Denise G. Simons-Morton, MD, PhD d a Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
b Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
c Departments of Biostatistics and Epidemiology, Mailman School of Public Health, and Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
d Clinical Applications and Prevention Branch, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA.
Address for reprints: Robert P. Byington, MPH, PhD, Wake Forest University School of Medicine, Department of Epidemiology and Prevention, Medical Center Boulevard, Winston-Salem, North Carolina 27157.
Le texte complet de cet article est disponible en PDF.
© 2007
Elsevier Inc. Tous droits réservés.
Vol 99 - N° 12S
P. S1-S3 - juin 2007 Retour au numéro
Article précédent
- Faculty Disclosures
- Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
- David C. Goff, Hertzel C. Gerstein, Henry N. Ginsberg, William C. Cushman, Karen L. Margolis, Robert P. Byington, John B. Buse, Saul Genuth, Jeffrey L. Probstfield, Denise G. Simons-Morton, ACCORD Study Group †
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?